A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

Inclusion Criteria Concurrent Medication: Allowed: * Pneumocystis prophylaxis. * Antiretroviral therapy, or other experimental protocols. * Antipyretics and analgesics as per the treating physician. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Unexplained fever. * Night sweats. * Unexplained anemia with hemoglobin \< 10 g percent or hematocrit less than 30 percent. * Hepatic transaminase elevations or total bilirubin values of \> 3 times normal. * Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Patients with the following are excluded: * Known hypersensitivity to clofazimine. * Mycobacterium avium complex (MAC) infection diagnosis at any site (except isolation from stool in asymptomatic patient). * Any of the following symptoms at the time of study entry: * Unexplained fever. * Night sweats. * Unexplained anemia with hemoglobin \< 10 percent or hematocrit less than 30 percent. * Hepatic transaminase elevations or total bilirubin values of \> 3 times normal. * Long-term (over 2 weeks) treatment with any drug with known significant anti-MAC activity. Prior Medication: Excluded: * Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Group 1: * AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) within 2 to 4 months prior to study entry. * Group 2: * Patients with T4 counts \< 100 cells/mm3, regardless of prior opportunistic infections or malignancies. * Karnofsky = or \> 70. * All patients must sign informed consent.